13F reference period
Q2 2026
Security Snapshot
Crescent Biopharma, Inc. - Common Stock (CBIO) Institutional Ownership
CUSIP: 38000Q201
13F Institutional Holders and Ownership History from Q4 2025 to Q2 2026
Institutions Reporting
2
Shares (Excl. Options)
472,913
Price
$18.00
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CBIO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 472,913
- Total 13F value
- $8,512,434
- Portfolio coverage rank
- 0%
- Share change
- -362,940
- Value change
- -$6,666,583
- Number of holders
- 2
- Shares outstanding
- 27,577,396
- SEC-reported price per share
- $18.00
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- CBIO - Crescent Biopharma, Inc. - Common Stock is tracked under CUSIP 38000Q201.
- 2 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 3 to 2 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $15,354,620 to $8,512,434.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 2 institutions filings for Q2 2026.
Security key
38000Q201
13F reference period
Q2 2026
13F holders
2
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
CBIO full holder history
CRESCENT BIOPHARMA, INC. SEC filings
CRESCENT BIOPHARMA, INC. company facts
CRESCENT BIOPHARMA, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 38000Q201:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
CBIO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BALYASNY ASSET MANAGEMENT L.P. | 6% | $29,932,506 | 1,662,917 | BALYASNY ASSET MANAGEMENT L.P. | 30 Jun 2026 | |||
| 1Globe Capital LLC | 10% | +64% | $20,839,816 | +$7,729,886 | 1,425,432 | +59% | 1Globe Capital LLC | 07 Oct 2025 |
| FMR LLC | 10% | 1,414,190 | FMR LLC | 30 Jun 2025 | ||||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 1,391,196 | Venrock Healthcare Capital Partners III, L.P. | 13 Jun 2025 | ||||
| Adage Capital Management, L.P. | 0.37% | 50,912 | Adage Capital Management, L.P. | 20 Jun 2025 |
As of 30 Jun 2026, 2 institutional investors reported holding 472,913 shares of Crescent Biopharma, Inc. - Common Stock (CBIO). This represents 1.7% of the company’s total 27,577,396 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
3
Headline period
Q2 2026
Rows shown
1-3 of 3